BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Fred Cohen Nominated to BioCryst’s Board’s List


Dallas, Texas 07/24/2013 (Financialstrend) – BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today made declaration that Fred E. Cohen, managing director, D.Phil., got elected to the firm’s board.

George B. Abercrombie, Chairman of the panel of BioCryst stated, “The Company’s directors and Leadership group of BioCryst are very happy to have Cohen become part of the firm’s Board.”

“Cohen brings a wealth of technical awareness and biz insight to the firm and has been a priceless resource to the group for many years as both a consultant and as a shareholder. We anticipate his leadership and insights in the direction of the further triumph of the company.”

In the year 2001, Dr. Fred got connected to TPG to begin TPG’s project attempts in bioengineering and biosciences, and he acts as a Partner and MD at TPG Biotech.

Dr. Fred has been an associate of the staff of University of California, San Francisco (UCSF) since the year 1986.

At UCSF, Dr. Fred has worked as an Internist for hospitalized people, a consulting medical specialist and as the head of the section of Endocrinology and Metabolism.

His study interests consist of structure based medicine design, prion illnesses, computational environmental science and heteropolymer chemical science. Fred’s investigation is best acknowledged in the arenas of protein arrangement and the configuration basis of prion ailment.

At present Dr. Fred is a part of the Board of Directors of Genomic Health, Quintiles Transnational and the panels of a number of privately held firms.

“Both peramivir as well as BCX4161 got detected utilizing structure based medicine design, an established approach to formulating strong and choosy inhibitors of accelerators involved in illness,” added up Dr. Fred. “With the current development in BioCryst’s inherited angioedema and peramivir flu growth plans, it is an exhilarating time to become part of its Board of Directors.”

BioCryst Pharmaceuticals, Inc. announced the outcome of stage 1 BCX4161 clinical trial, which is used for the cure of inherited Angioedema.